India, May 15 -- Enveric Biosciences (ENVB), a biotechnology company, on Friday reported its first quarter financial results, and provided further business updates.
The company specializes in developing neuroplastogens for the treatment of neurological disorders.
Q1 2026:
Net losses amounted to $1.63 million, or $1.08 per share, while in the same period in the prior year, the net loss was $2.18 million, or $14.58 per share.
Cash on hand as of March 31, 2026, amounted to $4.91 million.
Enveric gained $2.8 million in gross proceeds from a private offering in the first quarter. Additionally, the company raised $13.9 million in a private placement offering.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); }...